Doximity
DOCS
$28.58
+2.33%
Doximity, Inc. operates a leading digital platform purpose-built for U.S. healthcare professionals, offering a suite of tools spanning medical news and research, colleague collaboration, career management, on-call scheduling, documentation, and virtual patient visits, while monetizing its network primarily through Marketing Solutions sold to pharmaceutical companies and health systems, alongside Hiring Solutions for medical recruiting. As the largest professional network for U.S. physicians, Doximity occupies a uniquely defensible position as a two-sided platform connecting over a million verified clinicians with the life sciences industry, making it a distinct hybrid of a vertical social network and a high-margin healthcare marketing channel rather than a traditional SaaS vendor. The current investor narrative has swung violently between two poles: a May 2026 earnings-driven collapse on fears of a sharp revenue growth slowdown, followed by an August 2026 surge of roughly 30% after management highlighted that AI investments are delivering superior performance and 10x unit economics, reframing the company as an AI-enabled compounder. This debate — whether Doximity's AI-driven efficiency gains can reignite growth or merely mask a maturing core marketing business — is now the central question driving both the stock's extreme volatility and its depressed valuation relative to history.…
DOCS
Doximity
$28.58
Related headlines
Investment Opinion: Should I buy DOCS Today?
The synthesized recommendation is Hold. The core thesis is that Doximity is a high-quality, cash-generative business trading at a deep discount to its historical valuation, but near-term growth uncertainty and recent analyst downgrades warrant a cautious stance. The analyst consensus rating is "hold" with a recommendation mean of 2.62, and the average target price of $29.67 implies just 6.2% upside from the current price of $27.93. This suggests the stock is fairly valued after its recent run, with limited margin of safety.
Supporting evidence for the Hold rating includes: 1) Valuation is attractive on a forward basis, with a forward PE of 17.94x and PS of 6.76x, both below sector averages; 2) Profitability remains best-in-class with gross margin of 89.1% and net margin of 30.4%, though compressed from prior levels; 3) Free cash flow is robust at $299.3 million TTM, yielding 6.9%, and the balance sheet is debt-free with $273.6 million in cash; 4) Revenue growth has decelerated to 7.34% YoY, but the AI narrative could potentially reaccelerate growth. The implied upside to the average analyst target is modest at 6.2%, but the high target of $47 offers 68% upside if the bull case materializes.
Key risks that could invalidate the thesis include: 1) Continued revenue deceleration below 5% would likely lead to further multiple compression; 2) Failure of AI investments to contribute meaningfully to revenue could result in margin pressure without growth; 3) Competitive threats or regulatory changes could disrupt the core business. The rating would upgrade to Buy if revenue growth reaccelerates above 10% and margins stabilize, or if the stock pulls back to the low $20s providing a better entry point. It would downgrade to Sell if revenue growth turns negative or if AI investments fail to show traction. Relative to its history, the stock is undervalued, but relative to near-term growth prospects, it appears fairly valued. The market is pricing in a mature compounder, and any re-rating depends on execution.
Sign up to view all
DOCS 12-Month Price Forecast
Doximity presents a balanced risk/reward profile. The company's exceptional profitability, net cash position, and deeply discounted valuation provide downside support, while the AI narrative offers potential upside if growth reaccelerates. However, the recent revenue deceleration and analyst downgrades suggest caution. The stock is likely to remain range-bound until there is clearer evidence of a growth inflection. I would upgrade to bullish if revenue growth accelerates above 10% and margins stabilize, and downgrade to bearish if growth falls below 5% or if AI investments fail to show traction. The wide analyst target range ($18-$47) underscores the high uncertainty.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Doximity's 12-month outlook, with a consensus price target around $29.67 and implied upside of +3.8% versus the current price.
Average Target
$29.67
0 analysts
Implied Upside
+3.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $47
Analyst target range
Doximity is covered by 18 analysts, and the consensus recommendation is "hold" with a recommendation mean of 2.62 (where 1 is strong buy and 5 is strong sell), indicating a distinctly neutral-to-cautious stance. The average price target of $29.67 implies just 6.2% upside from the current price of $27.93, a modest expected return that reflects the market's uncertainty about whether the AI-driven August rally can be sustained; the consensus leans neutral rather than bullish, with the hold rating suggesting analysts see the stock as fairly valued after its recent run. The estimated EPS average of $2.05 (range of $1.99 to $2.12) and estimated revenue average of $863.1 million (range of $844.0 million to $887.4 million) imply roughly 7-8% revenue growth and a forward PE of approximately 13.6x at the current price, which would represent a significant earnings acceleration from the trailing $0.045 quarterly EPS if achieved. The target price range is exceptionally wide, spanning from a low of $18.00 to a high of $47.00 — a 161% spread that signals very low analyst conviction and high uncertainty about the company's trajectory. The high target of $47.00 implies roughly 68% upside and would require the AI investment thesis to deliver accelerating revenue growth, multiple expansion back toward 25-30x forward earnings, and successful monetization of new AI-powered products; the low target of $18.00 implies 36% downside and prices in continued revenue deceleration, margin compression from rising R&D, and competitive pressure on the core pharma marketing business. Recent institutional rating actions reveal a deteriorating sentiment trend: B of A Securities downgraded to Underperform from Buy on June 29, 2026, Wells Fargo downgraded to Underweight from Equal Weight on August 10, 2026, and Freedom Capital Markets cut to Hold from Buy on September 8, 2026, while only Piper Sandler maintained an Overweight rating. This pattern of downgrades — particularly the move to Underperform and Underweight — suggests that despite the August stock surge, sell-side analysts are growing more cautious on fundamentals, and the wide target spread combined with the recent downgrade cluster indicates that price discovery remains inefficient and volatility is likely to persist.
Drowning in data?
Find the real signal!
Bulls vs Bears: DOCS Investment Factors
The bear case currently has stronger evidence due to the confirmed revenue deceleration to 7.3% YoY and margin compression, which are tangible and recent. However, the bull case is gaining traction from the AI narrative, fortress balance sheet, and deep valuation discount. The single most important tension is whether AI investments can reignite revenue growth or merely mask a maturing core marketing business. If AI-driven products begin contributing meaningfully to revenue, the stock could re-rate significantly; otherwise, the deceleration may continue to pressure the multiple. The market is clearly divided, as evidenced by the wide analyst target range and recent downgrades despite the August rally.
Bullish
- Fortress balance sheet with net cash: Debt-to-equity is just 0.011 and current ratio is 6.09, with $273.6 million in cash. This provides enormous flexibility to fund AI R&D, buybacks, and weather a growth slowdown without external financing.
- Exceptional profitability and cash generation: Trailing gross margin is 89.1%, net margin 30.4%, and operating margin 33.3%. Free cash flow TTM is $299.3 million, yielding 6.9% FCF yield, with minimal capex of $62,000 in the latest quarter.
- Deeply discounted valuation vs. history and peers: Forward PE of 17.94x is below the S&P 500 average, while PS of 6.76x is down ~85% from its 2021 peak of 189x. Peers in healthcare information services often trade at 25-35x earnings and 5-8x sales.
- AI investments showing early traction: Management highlighted AI investments delivering superior performance and 10x unit economics, sparking a 32.6% single-day surge on August 7, 2026. This reframes the company as an AI-enabled compounder.
Bearish
- Severe revenue growth deceleration: Latest quarter revenue grew just 7.34% YoY to $156.6 million, down from 23.2% YoY in the year-ago quarter. This structural slowdown in the core marketing subscription business is the primary bear case.
- Margin compression from rising R&D: Net margin fell to 15.5% from 36.5% a year ago, and operating margin dropped to 21.5% from 37.4%, driven by R&D jumping to 24.6% of revenue from 18.4%. Investors need to see leverage materialize.
- Analyst downgrades and low conviction: Recent downgrades include B of A to Underperform (June 29), Wells Fargo to Underweight (Aug 10), and Freedom Capital to Hold (Sept 8). The target price range is extremely wide ($18-$47), signaling low conviction.
- High volatility and broken long-term momentum: Beta of 1.248 and max drawdown of -76.03% highlight extreme volatility. The stock is down 61.2% over the past year and remains 62% below its 52-week high of $74.33.
DOCS Technical Analysis
Doximity is in a recovery phase following a severe downtrend, with the stock down 61.2% over the trailing year but up 27.8% over the past three months and 22.7% over six months, signaling that a bottoming process is underway. At the current price of $27.93, the stock sits at approximately 18.8% of its 52-week range (low of $17.15, high of $74.33), a positioning that reflects deep prior damage but also substantial room to run before encountering overhead supply; the maximum drawdown of -76.03% underscores how violent the de-rating has been. This low-in-range positioning is a double-edged sword: it offers value-oriented entry for contrarians, but the sheer distance from the high confirms that long-term momentum remains broken and rallies are likely to be sold into until proven otherwise. Recent momentum is decisively positive and accelerating: the 1-month change of +6.12% and 3-month change of +27.77% both dwarf the S&P 500's respective +0.59% and +3.34% over the same periods, producing relative strength readings of +5.53 and +24.43. The most striking feature is the August 7, 2026 single-day gap from $20.66 to $27.40 (+32.6%) on earnings, which established a new trading regime and has held, with the stock consolidating between roughly $24 and $28 since. This divergence — a deeply negative 1-year trend (-61.2%) against strongly positive 3-month momentum — is characteristic of a mean-reversion rally off an oversold base rather than a confirmed new uptrend, and the failure to reclaim even $30 suggests the market is still testing conviction. Key technical levels are well-defined: support rests at the 52-week low of $17.15, with a secondary shelf around $20-$21 formed during the May-July basing period, while resistance sits at the 52-week high of $74.33 — far too distant to be immediately relevant — making the more actionable near-term resistance the $28.50-$30 zone where the stock has repeatedly stalled. A decisive breakout above $30 on volume would signal that the AI narrative is gaining institutional traction and could open a path toward the mid-$30s, whereas a breakdown below $24 would invalidate the post-earnings base and likely retest $20. With a beta of 1.248, Doximity is roughly 25% more volatile than the broader market, meaning position sizing should be conservative and stop-losses set with wider bands to avoid whipsaw in a name that has demonstrated 30%+ single-day moves.
Beta
1.22
1.22x market volatility
Max Drawdown
-76.0%
Largest decline past year
52-Week Range
$17-$74
Price range past year
Annual Return
-61.0%
Cumulative gain past year
| Period | DOCS Return | S&P 500 |
|---|---|---|
| 1m | +8.5% | +0.6% |
| 3m | +25.7% | +3.6% |
| 6m | +30.7% | +14.6% |
| 1y | -61.0% | +15.8% |
| ytd | -34.0% | +13.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOCS Fundamental Analysis
Doximity's revenue trajectory has decelerated meaningfully from its historical pace, with the most recent quarter (ending June 30, 2026) delivering $156.6 million in revenue at just 7.34% year-over-year growth — a sharp slowdown from the 23.2% YoY growth implied by the year-ago quarter's $145.9 million and the 9.8% growth seen in the December 2025 quarter ($185.1 million vs. $168.6 million). The sequential pattern reveals the strain: revenue fell from $185.1 million in Q3 (Dec 2025) to $145.4 million in Q4 (Mar 2026) to $156.6 million in Q1 (Jun 2026), and while some seasonality is normal for pharma marketing budgets, the YoY comparison of 7.3% versus the prior year's 23%+ growth confirms a structural deceleration. Segment data shows Subscription revenue of $146.3 million dwarfing Service/Other at $10.3 million, meaning the entire growth story hinges on the core marketing subscription business, which is precisely where the slowdown is concentrated — a concentration risk that explains the market's harsh reaction to guidance. Profitability remains exceptional even as growth slows: net income of $24.3 million in the latest quarter translated to a 15.5% net margin, while gross margin stood at 84.9% and operating margin at 21.5%, both figures that would be the envy of most software companies. However, margins have compressed notably from the year-ago quarter's 36.5% net margin and 37.4% operating margin, driven by a jump in R&D spending to $38.5 million (24.6% of revenue) from $26.8 million (18.4% of revenue) a year earlier — a deliberate AI investment that management argues will pay off but which is currently weighing on earnings. The trailing twelve-month net margin of 30.4% and gross margin of 89.1% remain best-in-class for the healthcare information services industry, suggesting the compression is investment-driven rather than competitive erosion, though investors will need to see R&D leverage materialize to validate the thesis. The balance sheet is fortress-like: debt-to-equity of just 0.011, a current ratio of 6.09, and $273.6 million in cash at the end of the latest quarter provide enormous financial flexibility, while trailing free cash flow of $299.3 million against a $4.36 billion market cap yields an attractive 6.9% FCF yield. ROE of 20.6% and ROA of 10.9% confirm efficient capital deployment, and the company has been aggressively returning capital via buybacks — repurchasing $91.6 million in the June 2026 quarter alone and $196.9 million in the December 2025 quarter — funded entirely from internal cash generation with zero debt repayment needs. The combination of high FCF conversion (FCF/OCF of 99.9% in the latest quarter), minimal capex ($62,000 in the June quarter), and a net cash position means Doximity has no external financing dependency, giving it the rare ability to fund AI R&D, buy back stock, and weather a growth slowdown simultaneously.
Quarterly Revenue
$156618000.0B
2026-06
Revenue YoY Growth
+7.3%
YoY Comparison
Gross Margin
84.9%
Latest Quarter
Free Cash Flow
$299285000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOCS Overvalued?
Because Doximity is solidly profitable with trailing net income of $24.3 million in the latest quarter and positive EPS of $0.045, the PE ratio is the appropriate primary metric; the stock trades at a trailing PE of 22.19x against a forward PE of 17.94x, and the 19.2% compression between the two implies the market expects meaningful earnings growth over the next twelve months, consistent with analyst EPS estimates of $2.05 versus the current run-rate. On a price-to-sales basis, the stock trades at 6.76x trailing sales and 6.72x EV/Sales, while the EV/EBITDA of 15.69x and price-to-free-cash-flow of 13.35x suggest the market is pricing Doximity more like a mature value stock than the high-growth SaaS name it was two years ago. The forward PE of 17.94x is particularly notable because it sits below the broader S&P 500's typical multiple, a stark reversal from Doximity's historical premium positioning. Comparing against the healthcare information services sector, where peers often trade at 25-35x earnings and 5-8x sales, Doximity's 22.2x trailing PE and 6.76x PS represent a discount to the higher-quality end of the peer group despite its 89.1% gross margin and 30.4% net margin being at or above sector best-in-class levels. The PEG ratio of -1.89 is distorted by the negative earnings growth rate in the trailing comparison and should be disregarded; more instructive is that the stock's PS of 6.76x is roughly half the 13.4x price-to-book and less than half the 13.35x PCF, indicating the market values the earnings stream far below the asset base — a classic sign of a de-rated growth stock. Relative to its own history, Doximity's current valuation is near multi-year lows: the PS ratio has collapsed from 24.2x in June 2026 and 44.9x in December 2025 to 6.76x today, while the PE has fallen from 39.9x and 33.5x to 22.2x, and the PB has dropped from 8.5x to 4.58x. This compression reflects both the stock price decline and the earnings base expansion, but the magnitude — PS down roughly 85% from its 2021 peak of 189x — suggests the market has fully repriced Doximity from a hyper-growth narrative to a mature compounder, leaving limited further downside from multiple contraction and creating potential for re-rating if AI-driven growth reaccelerates.
PE
22.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~77x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. Revenue growth has decelerated to 7.34% YoY, down from 23.2% a year earlier, and the entire growth story depends on the core subscription business, which is slowing. Margin compression is evident: net margin fell to 15.5% from 36.5%, and operating margin dropped to 21.5% from 37.4%, due to R&D spending rising to 24.6% of revenue from 18.4%. While the balance sheet is strong with debt-to-equity of 0.011 and $273.6 million in cash, the company must demonstrate that increased R&D yields revenue acceleration to justify the investment. Additionally, the concentration in subscription revenue ($146.3 million vs. $10.3 million in Service/Other) means any further slowdown in pharma marketing budgets could disproportionately impact results.
Market and competitive risks are elevated. The stock trades at a forward PE of 17.94x, which is below the S&P 500 average, but this discount reflects skepticism about growth. If revenue growth fails to reaccelerate, the multiple could compress further. The beta of 1.248 indicates 25% more volatility than the market, and the max drawdown of -76.03% shows the potential for severe declines. Competitive threats from other digital health platforms or changes in pharmaceutical marketing strategies could erode Doximity's moat. Recent analyst downgrades (B of A to Underperform, Wells Fargo to Underweight) highlight growing concerns about the sustainability of the AI-driven rally. Regulatory risks, such as changes in healthcare data privacy laws, could also impact operations.
Worst-case scenario: If revenue growth turns negative or stalls at low single digits, and AI investments fail to deliver, the stock could retest its 52-week low of $17.15, representing a 38.6% decline from the current price of $27.93. The analyst low target of $18.00 implies a 35.6% downside. A breakdown below the $24 support level would likely trigger a retest of the $20-$21 shelf, and if that fails, the 52-week low becomes the next target. Given the high volatility, such a move could happen rapidly, especially if the next earnings report shows continued deceleration or if downgrades accelerate. Investors could lose 35-40% from current levels in this adverse scenario.
FAQ
The key risks include: 1) Financial risk: revenue growth has slowed to 7.34% YoY, and margins have compressed, with net margin falling to 15.5% from 36.5%. 2) Competitive risk: Doximity faces competition from other digital health platforms and potential changes in pharmaceutical marketing strategies. 3) Macro risk: with a beta of 1.248, the stock is 25% more volatile than the market, and economic downturns could reduce pharma marketing budgets. 4) Company-specific risk: the AI investment thesis is unproven, and failure to monetize could lead to further multiple compression. The most severe risk is a continued revenue slowdown, which could drive the stock to its 52-week low of $17.15.
The 12-month forecast is neutral with a slight bullish tilt. The base case (55% probability) targets $28-$32, assuming revenue growth stabilizes in the high single digits and margins recover gradually. The bull case (25% probability) targets $40-$47, driven by AI-driven revenue acceleration and multiple expansion. The bear case (20% probability) targets $17-$20, if revenue growth turns negative and margins compress further. The most likely scenario is the base case, with the key assumption that AI investments begin to contribute incrementally without transforming growth. Analyst average target is $29.67, aligning with the base case.
DOCS appears undervalued relative to its history and peers. The forward PE of 17.94x is below the S&P 500 average, and the PS ratio of 6.76x is down ~85% from its 2021 peak of 189x. Peers in healthcare information services often trade at 25-35x earnings and 5-8x sales, suggesting a discount. However, the low valuation reflects the market's skepticism about future growth, given the revenue deceleration to 7.34% YoY. If AI investments reignite growth, the multiple could expand significantly; otherwise, the stock may remain cheap. The market is pricing in a mature compounder, so any growth acceleration would likely lead to re-rating.
Doximity is a good buy for value-oriented investors with a long-term horizon, but it carries significant near-term risks. The stock trades at a forward PE of 17.94x, below the S&P 500 average, and offers a 6.9% free cash flow yield, which is attractive. However, revenue growth has decelerated to 7.34% YoY, and analyst consensus is a hold with an average target of $29.67, implying only 6.2% upside. The biggest downside risk is a retest of the 52-week low of $17.15, representing 38.6% downside. For those who believe in the AI-driven growth story and can tolerate volatility, the risk/reward is favorable, but it is not a screaming buy at current levels.
DOCS is more suitable for long-term investment (minimum 2-3 years) given its high volatility (beta 1.248) and uncertain growth trajectory. The company does not pay dividends, so returns depend on capital appreciation. Short-term trading is risky due to the potential for sharp moves, as seen in the 32.6% single-day gain in August 2026 and the 61.2% decline over the past year. Long-term investors can benefit from the company's strong balance sheet, high margins, and potential AI-driven growth, but should be prepared for drawdowns. A suggested minimum holding period is 2-3 years to allow AI investments to mature and revenue growth to stabilize.
